CONTINUOUS VERSUS ON-DEMAND PROTON PUMP INHIBITOR TREATMENT FOR LARYNGOPHARYNGEAL REFLUX: A RANDOMIZED CLINICAL TRIAL

  • SUSYANA TAMIN Department of Otorhinolaryngology–Head and Neck Surgery, Faculty of Medicine, University of Indonesia–Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • ABDUL AZIZ RANI Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia–Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • ADANG BACHTIAR Department of Health Policy and Administration, Faculty of Public Health, University of Indonesia, Jakarta, Indonesia

Abstract

Objective: This study aimed to compare continuous and pro re nata (PRN) proton pump inhibitor (PPI) treatments for laryngopharyngeal reflux (LPR).


Methods: This randomized clinical trial included 52 LPR patients with lingual tonsil hypertrophy (LTH). Those patients who showed LPR improvement with an initial PPI trial were randomly divided into continuous and PRN PPI treatment groups. The Reflux Symptom Index (RSI) score, Reflux Finding Score (RFS), and LTH grade were used to assess the treatment results.


Results: The PPI treatment (30 mg of lansoprazole twice daily) for 6 mo resulted in a significantly decreasing RSI score (p<0.001). The PPI treatments for the first 8 w and the second 8 w also showed significant LPR improvement. However, there was no significant improvement after the third 8 w (p>0.05). After 6 mo, the PPI treatment also resulted in a continuous decrease in the RFS (p<0.001). There were no significant differences in the mean RSI scores (p=0.518) and mean RFSs (p=0.393) between the continuous and PRN PPI groups. In the grade II LTH cases, there was a significant improvement after 6 mo of PPI treatment (p<0.001), although there was no improvement after the first 2 mo in the treatment group. For the grade III LTH cases, there was no significant improvement after the first 2 mo and 6 mo of the PPI treatment.


Conclusion: Six months of PPI treatment improved the RSI score, RFS, and LTH grade, although there was no difference between the continuous and PRN PPI treatment groups.

Keywords: Laryngopharyngeal reflux, Proton pump inhibitor, Continuous, Pro re nata treatment

References

1. Chiba T. Laryngopharyngeal reflux disease (LPRD)–review article. Med Res Arch 2017;5:2–14.
2. Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assuncao AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol 2014;18:184-91.
3. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux symptom index (RSI). J Voice 2002;16:274-7.
4. Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001;111:1313-7.
5. Lechien JR, Huet K, Khalife M, Fourneau AF, Delvaux V, Piccaluga M, et al. Impact of laryngopharyngeal reflux on subjective and objective voice assessments: a prospective study. J Otolaryngol Head Neck Surg 2016;45:59.
6. Reimer C, Bytzer P. Management of laryngopharyngeal reflux with proton pump inhibitors. Ther Clin Risk Manag 2008;4:225–33.
7. Sato K, Umeno H, Chitose S, Nakashima T. Tetra-probe, 24 h pH monitoring for laryngopharyngeal reflux: a technique for simultaneous study of hypopharynx, esophagus and stomach. J Laryngol Otol Suppl 2009;31:117-22.
8. Chang BA, MacNeil SD, Morrison MD, Lee PK. The reliability of the reflux finding score among general otolaryngologists. J Voice 2015;29:572-7.
9. Ozturan O, Dogan R, Yenigun A, Veyseller B, Yildirim YS. Photographic objective alterations for laryngopharyngeal reflux diagnosis. J Voice 2017;31:78-85.
10. Habermann W, Schmid C, Neumann K, Devaney T, Hammer HF. Reflux symptom index and reflux finding score in otolaryngologic practice. J Voice 2012;26:e123-7.
11. Martinucci I, de Bortoli N, Savarino E, Nacci A, Romeo SO, Bellini M, et al. Optimal treatment of laryngopharyngeal reflux disease. Ther Adv Chronic Dis 2013;4:287–301.
12. Pearson JP, Parikh S, Orlando RC, Johnston N, Allen J, Tinling SP, et al. Review article: reflux and its consequences--the laryngeal, pulmonary and esophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston upon Hull, UK, 21–23 April 2010. Aliment Pharmacol Ther 2011;33 Suppl 1:1-71.
13. Sataloff RT, Hawkshaw MJ, Gupta R. Laryngopharyngeal reflux and voice disorders: an overview on disease mechanisms, treatments and research advances. Discovery Med 2010;10:213-24.
14. Patigaroo SA, Hashmi SF, Hasan SA, Ajmal MR, Mehfooz N. Clinical manifestations and role of proton pump inhibitors in the management of laryngopharyngeal reflux. Indian J Otolaryngol Head Neck Surg 2011;63:182-9.
15. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:528–34.
Statistics
1 Views | 3 Downloads
Citatons
How to Cite
TAMIN, S., RANI, A. A., & BACHTIAR, A. (2019). CONTINUOUS VERSUS ON-DEMAND PROTON PUMP INHIBITOR TREATMENT FOR LARYNGOPHARYNGEAL REFLUX: A RANDOMIZED CLINICAL TRIAL. International Journal of Applied Pharmaceutics, 11(6), 20-23. https://doi.org/10.22159/ijap.2019.v11s6.33530
Section
Original Article(s)